GlassScriptPhysician profile
Stephen Kye Richardson
NPI 1710918404
$51,175.94
in general payments reported to CMS, 2019-2025
32 companies · $2,550 in 2025
The $2,550 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.79 · 2020: $84.51 · 2021: $109 · 2022: $779 · 2023: $2,421 · 2024: $45K · 2025: $2,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $43K · Food and Beverage: $6,886 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $43,000.00 |
| Food and Beverage | $6,885.76 |
| Education | $266.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $43,000.00 | 2024 | |
| Abbvie INC. | $970.62 | 2021-2025 | |
| Ucb, INC. | $948.04 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $847.20 | 2021-2025 | |
| Genzyme Corporation | $573.75 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $446.40 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $391.45 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $378.35 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Organogenesis INC. | $347.38 | 2023-2025 | Puraply, Apligraf |
| Triad Life Sciences INC. | $341.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $307.77 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $289.97 | 2023-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $289.15 | 2023-2025 | Tremfya |
| Incyte Corporation | $281.91 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $237.83 | 2019-2025 | Taltz, Ebglyss |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $234.88 | 2024-2025 | Nemluvio, Aklief |
| Amgen INC. | $208.86 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $169.18 | 2022-2025 | |
| Dermavant Sciences, INC. | $148.74 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $146.88 | 2022-2024 | Ilumya |
| Kyowa Kirin, INC. | $125.58 | 2023-2025 | Poteligeo |
| Krystal Biotech INC | $114.50 | 2023-2024 | Vyjuvek |
| Stimlabs LLC | $77.68 | 2025 | Allacor P |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.69 | 2024-2025 | Cabtreo |
| Helsinn Therapeutics (U.S.), INC. | $50.51 | 2023-2025 | Valchlor |
| Allergan, INC. | $39.55 | 2019-2021 | |
| Biofrontera INC. | $21.33 | 2025 | Ameluz |
| Kerecis Limited | $16.07 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.00 | 2024 | |
| Cgg Medical INC | $15.18 | 2024 | |
| Vyne Pharmaceuticals INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.